Background {#Sec1}
==========

Antimicrobial exposure is the most important risk factor for *Clostridium difficile* infection (CDI) \[[@CR1]\]. Clindamycin, third-generation cephalosporins, and fluoroquinolones are generally considered the agents that pose the greatest risk \[[@CR1]\]. Restriction of these high-risk antibiotics may be a useful strategy to control CDI, but there is uncertainty regarding the selection of alternative agents that might have a lower propensity to cause CDI. Several recent studies have suggested that antibiotics with inhibitory activity against *C. difficile* (e.g., piperacillin/tazobactam, tigecycline, doxycycline, linezolid,) may pose a relatively low risk for CDI \[[@CR2]--[@CR7]\]. Moreover, Dubberke et al. \[[@CR7]\] recently reported that cephalosporin use was associated with acquisition of *C. difficile* colonization, whereas β-lactam-β-lactamase inhibitor combinations and metronidazole use were associated with loss of colonization. Substitution of piperacillin/tazobactam for third-generation cephalosporins has been associated with reductions in the incidence of CDI \[[@CR2], [@CR3]\]. Similarly, substitution of piperacillin/tazobactam for cephalosporins has been associated with reductions in colonization with vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriacae \[[@CR8], [@CR9]\]. In mice, piperacillin/tazobactam and tigecycline inhibited acquisition of *C. difficile* colonization during treatment \[[@CR10], [@CR11]\]. However, it is not known if these agents achieve sufficient concentrations in the intestinal tract to inhibit *C. difficile* colonization in patients. In fact, Wilcox et al. \[[@CR12]\] and Nord et al. \[[@CR13]\] found significant inter-patient variability in excretion of piperacillin and tazobactam in stool of patients.

One primary objective of this study was to test the hypothesis that antibiotics with inhibitory activity against *C. difficile* are infrequently associated with *C. difficile* colonization during treatment in hospitalized patients. A second primary objective was to determine if antibiotics with in vitro inhibitory activity against *C. difficile* achieve sufficient concentrations in stool to inhibit in vitro growth of *C. difficile*. Our analysis focused primarily on piperacillin/tazobactam because it is the most commonly used broad-spectrum agent in our facility.

Methods {#Sec2}
=======

Ethics statement {#Sec3}
----------------

The Cleveland VA Medical Center's Institutional Review Board approved the study protocol. All subjects provided verbal informed consent for specimen collection and medical record review.

Setting and participants {#Sec4}
------------------------

The Cleveland Veterans Affairs Medical Center is a 215-bed acute care hospital. During a 1-year period, intermittent point-prevalence culture surveys for asymptomatic carriage of toxigenic *C. difficile* were collected from consenting inpatients with no symptoms of CDI on 7 wards, including 3 medical wards, 1 surgical ward, a geriatric rehabilitation ward, a surgical intensive care unit, and a medical intensive care unit. The incidence of CDI was 7 cases per 10,000 patient-days during the study period with no outbreaks or clusters of CDI. Medical record review was conducted to obtain information on demographics, medical conditions, previous CDI, length of stay, antibiotic and subsequent development of CDI in the next 90 days. Based upon a modification of the classification scheme of Owens et al. \[[@CR1]\], antibiotics on the formulary were classified as having inhibitory activity against *C. difficile* that was moderate to good (i.e., ampicillin, amoxicillin, linezolid, metronidazole, imipenem, meropenem, piperacillin/tazobactam, tigecycline, tetracyclines) or poor (i.e., cephalosporins, ciprofloxacin, and trimethoprim/sulfamethoxazole). Intravenous vancomycin was not classified as inhibitory because it achieves relatively low levels in the intestinal tract \[[@CR14]\]. Moxifloxacin was classified as having variable activity against *C. difficile* because we have previously shown that isolates from our facility have variable susceptibility to moxifloxacin \[[@CR15]\]. For patients receiving multiple antibiotics concurrently, the regimen was classified as inhibitory if one agent had moderate to good inhibitory activity.

Microbiological methods {#Sec5}
-----------------------

Peri-rectal swabs or fresh stool specimens were collected and transferred to an anaerobic chamber (Coy Laboratories, Grass Lake, MI). Swabs or aliquots of stool were plated directly onto pre-reduced *C. difficile* Brucella Agar containing taurocholic acid and lysozyme (CDBA-TAL) and incubated for 48 h \[[@CR16]\]. In addition, to evaluate the possibility that carry over of antibiotics in stool to culture plates might result in false-negative cultures, all stool samples were serially diluted in phosphate-buffered saline to dilute any residual antibiotic and the dilutions were plated onto CDBA-TAL. Isolates were confirmed to be *C. difficile* on the basis of typical odor and appearance of colonies and by a positive reaction using *C. difficile* latex agglutination (Microgen Bioproducts, Camberly, UK). All *C. difficile* isolates were tested for in-vitro cytotoxin production using *C. difficile* Tox A/B II (Wampole Laboratories, Princeton, NJ), and isolates that did not produce toxin were excluded from the analysis.

In vitro assay for inhibitory activity in fecal suspensions {#Sec6}
-----------------------------------------------------------

To assess whether inhibitory concentrations of antibiotics were present in stool, a subset of patients whose fresh stool specimens were available after a minimum of 24 h of antibiotic treatment, were tested using a modification of the in vitro assay of colonization resistance developed by Borriello and Barclay \[[@CR17]\]. To determine if inhibitory activity persisted after discontinuation of antibiotics, stool specimens collected up to 2 weeks after discontinuation of antibiotics were also analyzed. Up to 3 stool samples were analyzed per patient. The test strain was an epidemic NAP1/027/BI strain (VA 17). The minimum inhibitory concentrations (MICs) of several commonly used antibiotics for VA 17 are shown in Table [1](#Tab1){ref-type="table"}. Fresh stool samples were homogenized in a 1:1 dilution of pre-reduced sterile water and inoculated with 10^4^ colony-forming units (CFU) per mL of vegetative *C. difficile* inside the anaerobic chamber. Serially-diluted samples were plated onto CDBA plates to determine the concentration of *C. difficile* immediately after inoculation and after incubation at 37 °C for 24 h. Samples with detectable levels of *C. difficile* prior to the inoculation of vegetative *C. difficile* were excluded. Specimens were considered inhibitory if the concentration of *C. difficile* decreased or remained unchanged compared to the baseline concentration. Inhibition of the *C. difficile* isolates was concurrently assessed in sterile filtrates of the stool suspensions. The filtrates were produced by centrifuging the suspensions at 10,000 rpm for 10 min, followed by filtering the supernatant through a 0.22 μm filter.Table 1Minimum Inhibitory Concentrations (MICs) of Commonly Used Antibiotics against the Clostridium difficile Test StrainAntibioticMIC (μg/mL)^a^Imipenem2Meropenem2Ampicillin2Piperacillin/tazobactam2Sulfamethoxazole/trimethoprim32Tetracycline0.5Ciprofloxacin128Moxifloxacin64Ceftriaxone32Clindamycin\>256Metronidazole0.25Linezolid0.5^*a*^MICs were determined by broth dilution. The test strain (VA 17) is an epidemic NAP1/027/BI strain

Statistical analysis {#Sec7}
--------------------

The frequency of asymptomatic carriage was compared for patients receiving piperacillin/tazobactam-containing or other inhibitory regimens versus those receiving non-inhibitory antibiotic regimens and/or prior antibiotics in the past 90 days. Log-binomial regression with robust variance estimation was used to model predictors of asymptomatic *C. difficile* carriage \[[@CR18]\]. This approach yields a prevalence ratio with 95 % confidence intervals. Student *t*- and Wilcoxon rank sum tests were used for normally and non-normally distributed data, respectively. Fisher's exact test was used to compare the proportions of stool suspensions that were inhibitory to growth of *C. difficile*. Data were analyzed with the use of SAS statistical software, version 9.1 (SAS Institute) and STATA 11 (StataCorp, College Station, TX).

Results {#Sec8}
=======

Frequency of and risk factors for asymptomatic carriage of *C. difficile* {#Sec9}
-------------------------------------------------------------------------

Of 250 patients screened, 32 (13 %) were asymptomatic carriers of *C. difficile* and 218 were non-carriers. There was no evidence of clustering of colonized patients on specific wards (range, 2 to 7 colonized patients on each ward). As shown in Table [2](#Tab2){ref-type="table"}, by bivariate analysis carriers were significantly more likely to have prior CDI or antibiotic treatment within 90 days. However, current antibiotic treatment was not associated with asymptomatic carriage. The length of stay at the time of culture collection was higher in those with asymptomatic carriage, but the difference was not statistically significant. Four of the asymptomatic carriers subsequently developed CDI, including 3 episodes of recurrent CDI and 1 initial episode.Table 2Characteristics of 32 Asymptomatic Carriers of *Clostridium difficile* and 218 Non-carriersCharacteristicAll participants (*N* = 250)Asymptomatic carriers (*N* = 32)Non-carriers (*N* = 218)*P* valueMean (SD) age (years)66.9 (11.9)64.3 (12.1)67.2 (11.8)0.19Median (IQR) days from admission to culture9 (4, 15)11.5 (6, 20.5)8 (4, 14)0.07Days from admission to culture 0--711013 (41)97 (44)0.34 8--14757 (22)68 (31) 15--21274 (12)23 (11) ≥22388 (25)30 (14)CDI in the previous 90 days136 (19)7 (3)\<0.001Antibiotics in the past 90 days15527 (84)128 (59)0.005Antibiotics in the past 30 days14424 (75)120 (55)0.03Current antibiotic treatment9812 (38)86 (39)0.83Comorbidities Heart disease959 (28)86 (39)0.22 Cancer8512 (37)73 (33)0.65 Diabetes10311 (34)92 (42)0.40 End stage renal disease233 (9)20 (9)0.97 Major surgery708 (25)62 (28)0.69 Spinal cord injury214 (13)17 (8)0.32Data are no. (%) of patients, unless otherwise specified. *SD* standard deviation, *IQR* interquartile range

Antibiotic therapy and *C. difficile* colonization {#Sec10}
--------------------------------------------------

Figure [1](#Fig1){ref-type="fig"} shows a comparison of the frequency of asymptomatic carriage of *C. difficile*, stratified by antibiotic treatment category. In comparison to patients receiving non-inhibitory antibiotics or prior antibiotics within 90 days, patients receiving current piperacillin/tazobactam were significantly less likely to be carriers of *C. difficile* (3 versus 18 and 22 %, respectively; *P* ≤ 0.02). Six of the 14 (43 %) patients with *C. difficile* carriage who had received prior antibiotics within 90 days had received regimens that included piperacillin/tazobactam. For the 6 patients who had received prior piperacillin/tazobactam, the mean number of days since the last dose of piperacillin/tazobactam was 7.5 (range, 2 to 14 days); for the 8 patients who received prior antibiotics other than piperacillin/tazobactam, the mean number of days since the last dose of antibiotics was 7.1 (range, 1 to 21 days). Patients receiving other inhibitory antibiotics were not less likely to be asymptomatic carriers than those receiving non-inhibitory antibiotics. Patients who had not received antibiotic therapy within the past 90 days were infrequently colonized with *C. difficile*.Fig. 1Frequency of asymptomatic carriage of toxigenic *Clostridium difficile* in hospitalized patients, stratified by antibiotic treatment classification. Based upon a modification of the classification scheme of Owens et al. \[[@CR1]\], antibiotics on the formulary that were classified as having inhibitory activity against *C. difficile* included ampicillin, amoxicillin, linezolid, metronidazole, imipenem, meropenem, piperacillin/tazobactam, tigecycline, and tetracyclines. Antibiotics on the formulary that were considered to have poor activity included cephalosporins, ciprofloxacin, and trimethoprim/sulfamethoxazole. Moxifloxacin was classified as having variable activity against *C. difficile*

Table [3](#Tab3){ref-type="table"} shows prevalence ratios of predictors of asymptomatic carriage generated using log-binomial regression analysis. Prior CDI and antibiotic use within 90 days were significant predictors of asymptomatic carriage, whereas current piperacillin/tazobactam use was protective in comparison to current non-inhibitory antibiotic use and/or antibiotic use in the past 90 days (*P* = 0.051).Table 3Prevalence Ratios of Predictors of Asymptomatic Carriage by Log-Binomial Regression AnalysisCharacteristicPrevalence ratio (asymptomatic carriage vs. non-carriage)95 % CI*P* valueAge (per year)0.980.96, 1.010.18Days from admission to culture (per day) 0--71.00Reference 8--140.790.33, 1.890.6 15--211.250.44, 3.550.67 ≥221.780.80, 3.970.16CDI in the previous 90 days4.212.11, 8.40\<0.001Any antibiotics0.930.48, 1.820.83Antibiotics in the past 90 days2.701.15, 6.330.02Antibiotics in the past 30 days2.201.03, 4.730.04Inhibitory antibiotic activity (vs. non-inhibitory activity) against *C. difficile* (among antibiotic users)0.410.14, 1.220.11Piperacillin/tazobactam (vs. non-inhibitory antibiotics only)0.140.02, 1.140.06Piperacillin/tazobactam (vs. non-inhibitory and or antibiotics in past 90 days)0.140.02, 0.990.05Comorbidities Heart disease0.640.31, 1.320.23 Cancer1.160.60, 2.270.65 Diabetes0.750.38, 1.480.41 End stage renal disease1.020.34, 3.100.97 Major surgery0.860.40, 1.820.69 Spinal cord injury1.560.60, 4.030.36*CI* Confidence interval

In vitro inhibitory activity of fecal suspensions {#Sec11}
-------------------------------------------------

Figure [2](#Fig2){ref-type="fig"} provides a comparison of the proportions of fecal suspensions that were inhibitory to in vitro growth of *C. difficile* strain VA 17 and the mean (+/− standard error) change in *C. difficile* concentration, stratified by the type of antibiotic treatment. One-hundred forty-one stool specimens collected from 98 total patients were analyzed (1--3 per patient). In comparison to suspensions from patients on non-inhibitory antibiotics or with prior antibiotic exposure within 90 days, current piperacillin/tazobactam therapy was associated with more frequent inhibition of *C. difficile* growth (71 versus 27 and 44 %, respectively; *P* = 0.03). In contrast, only 30 % of stool suspensions from patients with prior rather than current piperacillin/tazobactam therapy were inhibitory to *C. difficile* growth; the time of collection of the specimens after discontinuation of piperacillin/tazobactam ranged from 1 to 7 days. Suspensions from patients on other inhibitory antibiotics were associated with more frequent inhibition in comparison to suspensions from patients with prior antibiotic exposure (*P* = 0.004), but not in comparison to suspensions from patients on non-inhibitory antibiotics (*P* = 0.14). Suspensions from patients on moxifloxacin were not associated with more frequent inhibition than suspensions from patients with prior antibiotic exposure or on non-inhibitory antibiotics (*P* = 0.07).Fig. 2In vitro growth of *Clostridium difficile* in stool suspensions of hospitalized patients, stratified by level of in vitro inhibitory activity against *C. difficile* based on a modification of the classification of Owens et al. (1). A total of 141 stool specimens from 98 patients were analyzed (1--3 per patient). Specimens were considered inhibitory if the concentration of *C. difficile* decreased or remained unchanged compared to the baseline concentration. The non-inhibitory antibiotics that were administered at the time stool specimens were collected included ciprofloxacin (*N* = 6), ceftriaxone (*N* = 5), and cephalexin (*N* = 1). The agents classified as other inhibitory antibiotics that were administered included imipenem (*N* = 6), meropenem (*N* = 5), ertapenem (*N* = 6), linezolid (*N* = 4), ampicillin/sulbactam (*N* = 3), and metronidazole (*N* = 2). SE, standard error. CFU, colony-forming unit

Of the 28 stool specimens analyzed during current piperacillin/tazobactam therapy, 10 (36 %) were from patients receiving this agent in combination with other antibiotics. There was no difference in the percentage of inhibitory specimens for piperacillin/tazobactam administered as monotherapy versus in combination with other antibiotics (7/10, 70 % versus 13/18, 72 %, respectively; *P* = 1). Of the 19 stool specimens analyzed during therapy with other inhibitory antibiotics, 7 (37 %) were from patients receiving these agents in combination with other antibiotics. There was no difference in the percentage of inhibitory specimens for these inhibitory agents administered as monotherapy versus in combination with other antibiotics (3/7, 43 % versus 8/12, 67 %, respectively; *P* = 0.38).

For fecal suspensions of patients receiving inhibitory antibiotics, fecal filtrates produced from inhibitory suspensions consistently inhibited growth of *C. difficile*, suggesting that inhibition was due to the presence of antibiotics rather than bacteria. In contrast, a majority of fecal filtrates produced from inhibitory suspensions of patients receiving non-inhibitory antibiotics did not inhibit growth of *C. difficile*.

Discussion {#Sec12}
==========

Our findings suggest that piperacillin/tazobactam, an agent with activity against *C. difficile* that is excreted in significant concentrations in bile \[[@CR10]\], achieves sufficient concentrations in the intestinal tract of many patients to inhibit *C. difficile* colonization during treatment. Patients receiving piperacillin/tazobactam therapy were infrequently colonized with *C. difficile* in comparison to patients currently receiving agents lacking activity against *C. difficile.* Moreover, 71 % of fecal suspensions or filtrates from patients currently receiving piperacillin/tazobactam were inhibitory to in vitro growth of *C. difficile*. These data are consistent with previous studies in mice and in an in vitro human gut model \[[@CR10], [@CR19]\]. However, given previous evidence of significant inter-patient variability in excretion of piperacillin and tazobactam in stool \[[@CR12], [@CR13]\], we cannot exclude the possibility that the infrequent colonization with *C. difficile* in piperacillin/tazobactam-treated patients may be attributable to low intestinal drug concentrations in some patients. In conjunction with previous studies, our results provide evidence that *C. difficile* colonization may be reduced by formulary substitution of piperacillin/tazobactam for cephalosporins.

We did not find that patients receiving other antibiotics with inhibitory activity against *C. difficile* (predominantly carbapenems and ampicillin or amoxicillin) were infrequently colonized with *C. difficile* in comparison to those receiving non-inhibitory antibiotics. This finding could potentially be related to low levels of biliary excretion of some agents (e.g., imipenem-cilastatin, meropenem) \[[@CR20]\], or to inactivation in the intestinal tract (e.g., ampicillin may be inactivated in the colon by beta-lactamases) \[[@CR21]\]. However, further studies are needed because the number of patients evaluated was limited, particularly for doxycycline and metronidazole.

We found relatively high rates of asymptomatic carriage of *C. difficile* in patients not on current antibiotics but who had received antibiotic therapy within the past 90 days. Moreover, only 15 % of stool samples tested from these patients were inhibitory to growth of *C. difficile*. These findings are consistent with recent studies that demonstrate that antibiotic therapy may result in prolonged disruption of the indigenous intestinal microbiota \[[@CR22], [@CR23]\]. Because piperacillin/tazobactam may cause disruption of the indigenous microbiota that persists after therapy, it should be appreciated that this agent may have a biphasic effect on colonization with *C. difficile* (i.e., inhibition during therapy but promotion after therapy during the period of recovery of the microbiota) \[[@CR10]\]. Only 30 % of stool suspensions collected during the 2 week period after discontinuation of piperacillin/tazobactam were inhibitory to *C. difficile* and asymptomatic carriage was common after discontinuation of piperacillin/tazobactam (i.e., 43 % of carriers who had received prior antibiotics had received piperacillin/tazobactam).

Our study has several limitations. First, the study population included only men, a majority of whom were elderly. Additional studies are needed in other patient populations. Second, we collected a single rectal culture from many of the patients and therefore it is not known if the positive cultures represent persistent versus transient colonization. Third, our study may underestimate the true prevalence of asymptomatic carriage if many patients carry spores at levels below the limit of detection of our methods (\~2 log~10~colony-forming units/gm of stool). Fourth, we did not examine susceptibility patterns of *C. difficile* specific to our institution. Fifth, as noted previously, more data is needed to evaluate the potential for agents such as doxycycline and linezolid to inhibit *C. difficile* colonization. Finally, we evaluated whether inhibitory antibiotics were associated with reduced asymptomatic carriage of *C. difficile*. Future studies are needed to determine whether inhibitory antibiotics reduce the risk for infection during therapy.

Conclusions {#Sec13}
===========

Our findings demonstrate that piperacillin/tazobactam, an agent with activity against *C. difficile*, achieves sufficient concentrations in the intestinal tract of many patients to inhibit *C. difficile* colonization during treatment. These data suggest that *C. difficile* colonization may be reduced with the use of piperacillin/tazobactam compared to other regimens that are non-inhibitory to *C. difficile*. Further studies are needed to determine if formulary substitutions favoring use of piperacillin/tazobactam over cephalosporins might have an impact on CDI rates. Based on our findings, the potential impact of such formulary substitutions may be limited by the fact that piperacillin/tazobactam causes disruption of the indigenous microbiota that persists after therapy is discontinued.
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